Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + sonidegib
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination of two antineoplastic agents, docetaxel and sonidegib, investigated for the treatment of advanced cancers such as triple-negative breast cancer (TNBC). Docetaxel is a taxane-class chemotherapeutic that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis. Sonidegib is an oral small molecule inhibitor of the Hedgehog signaling pathway via antagonism of Smoothened (SMO), developed by Novartis. The combination has been studied in phase I clinical trials for advanced TNBC to determine safety, tolerability, and preliminary efficacy. At recommended doses—docetaxel 75 mg/m² IV every 21 days plus oral sonidegib up to 800 mg daily—the regimen showed manageable toxicity and some antitumor activity[1][2]. Sonidegib is FDA-approved as monotherapy for locally advanced basal cell carcinoma but remains investigational in this combination.
- Other names
- erismodegib
02
Targets
SMO (Smoothened)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + sonidegib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + sonidegib.